Acc2014 4
22
Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
-
Upload
astrazenecaoz -
Category
Health & Medicine
-
view
23 -
download
0
description
Acc2014 4
Transcript of Acc2014 4
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Renal denervation for uncontrolled hypertension: SYMPLICITY HTN-3 trial
Commentary:
Associate Professor John YiannikasConcord Hospital, Sydney
Associate Professor Chris ZeitzQueen Elizabeth Hospital, Adelaide
Dr Greg BellamyJohn Hunter Hospital, Newcastle
Late-breaking trial
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Change in office SBP at 6 months
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Change in mean ambulatory SBP at 6 months
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Australia was an ‘early adopter’ of renal denervation for resistant hypertension: the treatment is not approved in the US.
• SYMPLICITY HTN-3 has the strengths associated with a randomised and blinded trial and the use of a sham intervention as a control.
• A 12 mmHg reduction in SBP in the control group may have resulted from better medication adherence and other factors associated with enrolment in a clinical trial. It suggests scope to improve blood pressure through conventional means even in ‘treatment resistant’ patients.
• There was no objective assessment of medication adherence in the study: adherence was assessed by patient diaries.
Commentary: A/Prof John Yiannikas, A/Prof Chris Zeitz, Dr Greg Bellamy
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• There is currently no biomarker of the success of denervation. Although there may have been a learning curve for the procedure, it was provided by experienced interventionalists.
• Based on SYMPLICITY HTN-3, it would be prudent to provide renal denervation only within a clinical trial, until an agreed biomarker of successful denervation is established.
• Renal denervation could be considered in isolated patients with recurring hypertensive crisis on truly maximal therapy, until further studies define its role.
• The cost-effectiveness of the procedure needs to be defined.
Commentary: A/Prof John Yiannikas, A/Prof Chris Zeitz, Dr Greg Bellamy
![Welcome [s3.eu-central-1.amazonaws.com]...bb bb bb bb bb # # # # # b b bb bb bb bb bb bb bb bb 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 44 4](https://static.fdocuments.us/doc/165x107/5e9f761d9d1aa23b1a09f03e/welcome-s3eu-central-1-bb-bb-bb-bb-bb-b-b-bb-bb-bb-bb-bb-bb-bb.jpg)
![Oh Pretty Woman4sc].pdfã ### ### ### ### ### ### ### ### 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4](https://static.fdocuments.us/doc/165x107/60cfb349cd0cbb00d32b6774/oh-pretty-woman-4scpdf-4-4-4-4-4-4-4-4-4-4.jpg)
